Deal Watch: Flagship Ventures Doubles Down On Microbiome
Two of the VC's biotechs merged to create an immuno-microbiome company, while Seres is working with Emulate on better tech for microbiome research. UK specialty pharma Martindale acquired small hospital products-focused UK firm Viridian, and Bayer and X-Chem expanded their drug discovery alliance.
You may also be interested in...
Deal Watch: Success Nets CytomX Another $200m From BMS, Up To $3.6bn For Milestones
Bristol-Myers Squibb expanded its collaboration with CytomX for $200m up front and up to $3.6bn in milestone fees. Also, Takeda spun out eight non-core molecules into a new joint venture and X-Chem executed two deals with Japanese partners, among other recent deals.
Tech Transfer Roundup: Voyager Brings Home Pair Of CNS Collaborations
Collaboration with Washington University to co-develop therapies targeting apoliprotein A makes up part of Denali's big August push in Alzheimer's. Kleo gets global rights to two Yale antibody programs and raises Series A cash.
Lilly Teams Up With Boehringer Ingelheim To Boost Abemaciclib
The two big pharmas are working together in oncology in an effort to advance combination therapies in both their growing, but young oncology pipelines.